T-cell Malignancies Represent Small Fraction of the Reported Secondary Cancers following CAR-T in the FDA’s Adverse Event Reporting System
Analysis reveals that T-cell malignancies accounted for 0.1% of reports submitted to FDA following CAR T-cell therapy (WASHINGTON, March 14, 2024) – An analysis published today in Blood found that secondary cancers following CA...
Read moreASH Statement on Introduction of Health Home Legislation for People Living with Sickle Cell Disease
Reps. Burgess and Davis introduce bipartisan bill aimed at enhancing the quality of care for individuals living with SCD through Medicaid (WASHINGTON, February 29, 2024) – Congressional sickle cell disease (SCD) champions, Reps. Michael C...
Read moreCombination Therapy Lowers Blood Pressure in Patients Receiving Ibrutinib
Study suggests optimal therapy may differ for pre-existing versus new-onset hypertension (WASHINGTON, Feb. 5, 2024) – Combination treatments with two or more blood pressure drugs can significantly reduce blood pressure in patients taking ibrutinib, a...
Read moreAmerican Society of Hematology Announces 2024 Scholar Award Recipients
(WASHINGTON, Feb. 1, 2024) — The American Society of Hematology (ASH) today announced the 36 recipients of its 2024 Scholar Awards. One of ASH’s most prestigious research award programs, the ASH Scholar Award supports early career investi...
Read moreASH Supports CMMI’s Cell & Gene Therapy Access Model for Sickle Cell Disease
(WASHINGTON, January 31, 2024) – The Centers for Medicare & Medicaid Innovation Center (CMMI) published the Cell & Gene Therapy (CGT) Access Model for Sickle Cell Disease, which aims to improve access to gene therapies treatments for people w...
Read moreMohandas Narla DSc Begins Term as 2024 ASH President
(WASHINGTON, Jan. 9, 2024) — Mohandas Narla, DSc, distinguished scientist at New York Blood Center Enterprises, will serve as president of the American Society of Hematology (ASH) for a year-long term through December 2024. Dr. Narla is...
Read moreLiso-cel is a Cost Effective Second-line Treatment for Common Form of Lymphoma
First of its kind study evaluates liso-cel cost effectiveness through societal costs and benefits. (WASHINGTON, Dec. 28, 2023) – Lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, is a cost effective second line treatment for relapsed and re...
Read moreStudy Finds That Severe Long-Term Complications of Pulmonary Embolism in Children Are Rare
Findings show children with underlying medical conditions are at heightened risk, highlight importance of physical activity to prevent most common complications. (WASHINGTON, Dec. 26, 2023) – In the first study to comprehensively examine...
Read moreStudy Suggests COVID-19 Vaccine Safe and Effective for Individuals with Sickle Cell Disease
ASH Research Collaborative Publishes Preliminary Results of Largest Prospective mRNA Vaccine Efficacy Trial in Individuals with SCD to Date (SAN DIEGO, Dec. 12, 2023) – New research presented by the ASH Research Collaborative (ASH RC) dur...
Read moreModified Stem Cell Transplant Procedure Shows Favorable Results in Adults Living with Severe Sickle Cell Disease
Less Toxic Approach to Haploidentical Bone Marrow Transplantation in Adults Living with Severe Sickle Cell Disease Offers Promise LBA-4: Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT...
Read more- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10